Tag: Alter

Ruxolitinib cream 1.5% (Opezlura) was approved by the US Food and Drug Administration (FDA) this July for the treatment of nonsegmental vitiligo—a novel, breakthrough indication for a topical JAK inhibitor in a space with few options. Incyte’s agent may be next considered for a chronic skin disease with a more robust armamentarium: atopic dermatitis, which […]